Pre-Clinical Pharmacology and Antimicrobial Evaluation

In Vitro Potency Evaluation of Antimicrobials

SSI houses extensive collections of clinical isolates, including WHO priority pathogens, enabling robust evaluation of new antimicrobial agents. We provide a wide range of in vitro assays tailored to your research needs:

• Minimum inhibitory and bactericidal concentration determination (MIC/MBC)
• MIC50 and MIC90 determination
• Checkerboard MIC assays
• Growth kinetics and time-kill activity
• Post-antibiotic effect studies
• Frequency and development of resistance

All assays are conducted in accordance with EUCAST and CSLI guidelines, with the option to adapt or customize protocols as required.

In Vivo Pharmacology

Our experienced pre-clinical team conducts tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) studies in both naïve and infected mouse models. Multiple routes of administration are supported, including subcutaneous (SC), intravenous (IV), oral (PO), intramuscular (IM), and intranasal (IN).
Our in vivo pharmacology services include:

• Tolerability studies
• Pharmacokinetic profilin
• Pharmacodynamic assessments

In Vio Efficacy Evaluation in Murine Infection Models

SSI offers a comprehensive range of validated murine infection models to assess the in vivo efficacy of novel antimicrobial drugs. These models are ideal for efficacy screening, proof-of-concept, and PK/PD studies in the discovery phase.
Available infection models include:

• Peritonitis / Septicemia
• Thigh infection
• Urinary tract infection
• Skin infection
• Pneumonia
• Fungal sepsis
• Gastrointestinal colonization

Custom models can also be developed upon request.

Antimicrobial Susceptibility Testing

SSI provides expert evaluation of antimicrobial susceptibility and diagnostic performance through:

• Assessment of antimicrobial susceptibility testing methods
• Evaluation of new in vitro diagnostic tools
• Typing of microbial strains

Research Collaborations

In addition to providing CRO services, SSI actively participates as a research partner in national and international collaborative consortia focused on antimicrobial resistance and drug discovery.
Current collaborations include:

• ENABLE-2 – Uppsala University
• COMBINE – IMI AMR Accelerator
• MURYXIN Project – JPIAMR

Publication references of inhouse infection models

1. D Vera-Yunca, C S Matias, C Vingsbo Lundberg, L E. Friberg. Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: From in vitro time-kill experiments to a mouse pneumonia model. 2025 J Antimicrob Chemother 2025; 80:1860-1868
   
   
2. I Hernández-Lozano, V Aranzana Climent, S Cao, C Matias,J U Hansen, E Liepinsh, D Hughes, S N Hobbie, C Vingsbo Lundberg, L Friberg. Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections. J Antimicrob Chemother 2025; 80: 301–310
   
   
3. J S Jørgensen, A Wester; C Sofia Silva Matias; L Cavaco; C Vingsbo Lundberg, C Brolin, E H Mood, D Żabicka, M Tomczak, M Urbas, F Björkling, PE. Nielsen, H Franzyk. Structure-activity study of oncocins modified with cationic polar moieties at the termini. European J of Medicinal Chemistry Report vol15 Dec 2025; 15: DOI: 10.1016/j.ejmcr.2025.100284
   
   
4. N Frimodt-Møller, J U. Hansen, M Plattner, D L. Huseby, S R Almind, K Haldimann, M Gysin, A Petersson, O Ercan, L Ganz, D Hughes, C Vingsbo Lundberg, S N. Hobbie. Apramycin efficacy against carbapenem- and aminoglycoside-resistant Escherichia coli and Klebsiella pneumoniae in murine blood stream infection models. International Journal of Antimicrobial Agents 2024. 
   
   
5. R Arrazuria, B Kerscher, K E Huber, J L. Hoover, C Vingsbo Lundberg, J U Hansen, S Sordello, S Renard, V Aranzana-Climent, D Hughes, P Gribbon, L E. Friberg, I Bekeredjian-Ding
   Expert Workshop Summary: Advancing towards a standardized murine model to evaluate treatments for AMR lung infection. Front. Microbiol., 08 September 2022 Sep 8:13:988725.
   
   
6. E Delavenne, A Weiß, C Matias, et.al. Topical Niclosamide (ATx201) Reduces Staphylococcus aureus Colonization and Increases Shannon Diversity of The Skin Microbiome in Atopic Dermatitis Patients in a Randomized, Double-blind, Placebo-controlled Phase 2 Trial. Clin Transl Med. 2022 May; 12(5):e790.
   
   
7. J Brem, T Panduwawala, JU Hansen, et al. Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors. Nat Chem. 2022 Jan;14(1):15-24. PubMed
   
   
8. Keating, S.M., Mizrahi, R.A., Adams, M.S. et al. Generation of recombinant hyperimmune globulins from diverse B-cell repertoires. Nat Biotechnol. 39(8): 989–999 (2021). Nature Biotechnology
   
   
9. L Jakobsen, C Vingsbo Lundberg, and N Frimodt-Møller. Ciprofloxacin pharmacokinetics/pharmacodynamics (PKPD) against susceptible and low-level resistant Escherichia coli in an experimental ascending urinary tract infection model in mice. Antimicrob Agents Chemother. 2020 Dec 16;65(1)
   
   
10. M Vaara, T Vaara, C Vingsbo Lundberg. Polymyxin derivatives NAB739 and NAB815 are more effective than polymyxin B in murine Escherichia coli pyelonephritis. J Antimicrob Chemother. 2018. 73(2):452-455
    
    
11. C Vingsbo Lundberg, N Frimodt-Møller. Efficacy of topical and systemic antibiotic treatment of methicillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents 2013. 42:272-275
    
    
12. C Vingsbo Lundberg, T Vaara, N Frimodt-Møller, M Vaara. Novel Polymyxin derivatives are effective in treating experimental E. coli peritoneal infection in mice. J Antimicrob Chemother. 2010 65(5):981-5.